B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors

Immune profile of B and T cells and tertiary lymphoid structures (TLSs) may differ in tumors of lung cancer (LC) patients with/without chronic obstructive pulmonary disease (COPD), and may also influence patient survival. We sought to analyze: (1) TLSs, germinal centers (GCs), B and T cells, and (2)...

Descripción completa

Detalles Bibliográficos
Autores: Tang, Jun|||0000-0001-9141-3537, Curull Serrano, Víctor|||0000-0003-2709-7431, Wang, Xuejie|||0000-0003-1398-3942, Mateu-Jiménez, Mercé, Pijuan, Lara|||0000-0002-9978-6933, Duran-Jordà, Xavier|||0000-0001-8517-9254, Qin, Liyun, Rodríguez-Fuster, Alberto|||0000-0002-4900-6126, Aguiló Espases, Rafael, Barreiro, Esther|||0000-0003-2708-3443, Ramis-Cabrer, Daniel|||0000-0001-7793-773X
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:233646
Acceso en línea:https://ddd.uab.cat/record/233646
https://dx.doi.org/urn:doi:10.3390/cancers12092644
Access Level:acceso abierto
Palabra clave:Lung cancer
Chronic respiratory diseases
Tertiary lymphoid structures
B cells
Overall survival
Descripción
Sumario:Immune profile of B and T cells and tertiary lymphoid structures (TLSs) may differ in tumors of lung cancer (LC) patients with/without chronic obstructive pulmonary disease (COPD), and may also influence patient survival. We sought to analyze: (1) TLSs, germinal centers (GCs), B and T cells, and (2) associations of the immune biomarkers with the patients' 10-year overall survival (OS). TLSs (numbers and area), B [cluster of differentiation (CD) 20], and T (CD3), and GCs cells were identified in both tumor and non-tumor specimens (thoracotomy) from 90 LC-COPD patients and 43 LC-only patients. Ten-year OS was analyzed in the patients. Immune profile in tumors of LC-COPD versus LC: TLS numbers and areas significantly decreased in tumors of LC-COPD compared to LC patients. No significant differences were observed in tumors between LC-COPD and LC patients for B or T cells. Immune profile in tumors versus non-tumor specimens: TLS areas and B cells significantly increased, T cells significantly decreased in tumors of both LC and LC-COPD patients. Survival: in LC-COPD patients: greater area of TLSs and proportion of B cells were associated with longer survival rates. The immune tumor microenvironment differs in patients with underlying COPD and these different phenotypes may eventually impact the response to immunotherapy in patients with LC.

Similares en LA Referencia